In laboratory and clinical studies, intravesical electromotive drug administration increased
mitomycin bladder uptake, improving clinical efficacy in high-risk non-muscle invasive
urothelial bladder cancer. The investigators' aim was to compare transurethral resection of
bladder tumor and adjuvant intravesical electromotive mitomycin with transurethral resection
and adjuvant intravesical passive diffusion mitomycin and transurethral resection alone in
patients with primary stage pTa-pT1 and grade G1-G2 urothelial bladder cancer Patients will
be randomly assigned to: transurethral resection alone, transurethral resection and adjuvant
intravesical 40 mg passive diffusion mitomycin dissolved in 50 ml sterile water infused over
60 minutes once a week for 6 weeks, or transurethral resection and adjuvant intravesical 40
mg electromotive mitomycin dissolved in 100 ml sterile water with 23 mA pulsed electric
current for 30 minutes once a week for 6 weeks. Patients in the intravesical adjuvant
electromotive and passive diffusion mitomycin groups who are disease-free 3 months after
induction treatment, will be scheduled to receive monthly intravesical instillation for 10
months, with the same dose and methods of infusion as initial assigned treatment. All
patients will be assessed for safety. The investigators' primary endpoints are recurrence
rate and disease-free interval. Analyses will be done by intention to treat.